135 related articles for article (PubMed ID: 32796361)
61. Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.
Baillet P; Cadiot G; Goutte M; Goutorbe F; Brixi H; Hoeffel C; Allimant C; Reymond M; Obritin-Guilhen H; Magnin B; Bommelaer G; Pereira B; Hordonneau C; Buisson A
World J Gastroenterol; 2018 Feb; 24(5):641-650. PubMed ID: 29434453
[TBL] [Abstract][Full Text] [Related]
62. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease.
Höög CM; Bark LÅ; Broström O; Sjöqvist U
Scand J Gastroenterol; 2014 Sep; 49(9):1084-90. PubMed ID: 24853318
[TBL] [Abstract][Full Text] [Related]
63. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
Schaffer T; Schoepfer AM; Seibold F;
J Crohns Colitis; 2014 Sep; 8(9):1125-32. PubMed ID: 24636141
[TBL] [Abstract][Full Text] [Related]
64. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease.
Brand EC; Elias SG; Minderhoud IM; van der Veen JJ; Baert FJ; Laharie D; Bossuyt P; Bouhnik Y; Buisson A; Lambrecht G; Louis E; Pariente B; Pierik MJ; van der Woude CJ; D'Haens GRAM; Vermeire S; Oldenburg B;
Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1704-1718. PubMed ID: 31881273
[TBL] [Abstract][Full Text] [Related]
65. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease.
Pavlidis P; Gulati S; Dubois P; Chung-Faye G; Sherwood R; Bjarnason I; Hayee B
Scand J Gastroenterol; 2016 Dec; 51(12):1447-1452. PubMed ID: 27400728
[TBL] [Abstract][Full Text] [Related]
66. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
67. Prospective evaluation of the clinical utility of interferon-γ assay in the differential diagnosis of intestinal tuberculosis and Crohn's disease.
Kim BJ; Choi YS; Jang BI; Park YS; Kim WH; Kim YS; Jung SA; Han DS; Kim JS; Choi JH; Choi CH; Jeen YT; Cheon JH; Ye BD; Yang SK; Kim YH
Inflamm Bowel Dis; 2011 Jun; 17(6):1308-13. PubMed ID: 21053248
[TBL] [Abstract][Full Text] [Related]
68. Antitubercular Therapy Given to Differentiate Crohn's Disease From Intestinal Tuberculosis Predisposes to Stricture Formation.
Gupta A; Pratap Mouli V; Mohta S; Kante B; Kalaivani M; Madhu D; Sahu P; Kumar S; Sharma R; Sahni P; Das P; Gupta SD; Makharia G; Kedia S; Ahuja V
J Crohns Colitis; 2020 Nov; 14(11):1611-1618. PubMed ID: 32369567
[TBL] [Abstract][Full Text] [Related]
69. The diagnostic accuracy of faecal calprotectin and small bowel capsule endoscopy and their correlation in suspected isolated small bowel Crohn's disease.
Hale MF; Drew K; McAlindon ME; Sidhu R
Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1145-50. PubMed ID: 27384306
[TBL] [Abstract][Full Text] [Related]
70. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
[TBL] [Abstract][Full Text] [Related]
71. Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
Shentova R; Baycheva M; Kofinova D; Hadjiiski P; Yaneva P
Folia Med (Plovdiv); 2020 Jun; 62(2):271-275. PubMed ID: 32666743
[TBL] [Abstract][Full Text] [Related]
72. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
73. Development and validation of visceral fat quantification as a surrogate marker for differentiation of Crohn's disease and intestinal tuberculosis.
Yadav DP; Madhusudhan KS; Kedia S; Sharma R; Pratap Mouli V; Bopanna S; Dhingra R; Pradhan R; Goyal S; Sreenivas V; Vikram NK; Makharia G; Ahuja V
J Gastroenterol Hepatol; 2017 Feb; 32(2):420-426. PubMed ID: 27532624
[TBL] [Abstract][Full Text] [Related]
74. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
[TBL] [Abstract][Full Text] [Related]
75. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.
Orlando A; Modesto I; Castiglione F; Scala L; Scimeca D; Rispo A; Teresi S; Mocciaro F; Criscuoli V; Marrone C; Platania P; De Falco T; Maisano S; Nicoli N; Cottone M
Eur Rev Med Pharmacol Sci; 2006; 10(1):17-22. PubMed ID: 16494106
[TBL] [Abstract][Full Text] [Related]
76. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
77. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
78. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
[TBL] [Abstract][Full Text] [Related]
79. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease.
Penna FGC; Rosa RM; Pereira FH; Cunha PFS; Sousa SCS; Ferrari TCA; Cara C; Ferrari MLA
Gastroenterol Hepatol; 2021 Feb; 44(2):87-95. PubMed ID: 32680729
[TBL] [Abstract][Full Text] [Related]
80. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
